DGAT2 and metabolic dysfunction-associated steatohepatitis: A systemic DGAT2 inhibitor, together with a liver-targeted ACC inhibitor, is now under clinical trials for the treatment MASLD/MASH, which works by reducing hepatic lipogenesis.75